Saitama Actemra study for QOL in patients with Rheumatoid arthritis

Saitama Actemra study for QOL in patients with Rheumatoid arthritis - SAQRA study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014484

Enrollment

Registered

2014-12-01

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

Treatment with Tocilizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients are fulfilled ACR clsssification ctiteria of 1987 and diagnosed as RA. 2.Patients have not been treated with tocilizumab. 3.Patients have not been treated with other biologics. 4.Patients are not have good response after treatnent with 6mg of MTX more than 4 weeks. 5.Patients are 20 and or more than 20 yeras old. 6.Patients fully understand and agree with this study with a letter of consent.

Exclusion criteria

Exclusion criteria: 1.Patients who have risk factors for infection. 2. Patients are not have depressive disorders.

Design outcomes

Primary

Measure	Time frame
QOL measured by SF-36 at 54 week	—

Countries

Japan

Contacts

Public ContactShigeto Kobayashi

Juntendo University, Juntendo Koshigaya Hospital Rheumatology, Internal Medicine

shigeto@juntendo.ac.jp048-975-0321

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026